$0.40▴ 3.61%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-10.07MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+1.6%year over year
Watch
Revenue growth has flattened.
Leverage
Moderatedebt to assets
Watch
Elevated leverage worth keeping an eye on.
More coming: dilution / share-count creep.
✦ The read
Cytosorbents Corporation is pre-profit. It is still burning cash while pre-profit. Revenue growth has flattened. Elevated leverage worth keeping an eye on.
Key numbers
Valuation
EPS (TTM)$-0.19
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin-31.9%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$37.20M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.